Qiming Venture Partners Announces Closing of Funds Totaling US$3.2 Billion

12 July 2022 | Tuesday | News


Qiming Venture Partners announced today the closing of its latest funds totaling US$3.2 billion, including USD Fund VIII at US$2.5 billion and the first closing of RMB Fund VII at RMB 4.7 billion (or US$ 700 million).
Image Source : Public Domain

Image Source : Public Domain

As in prior funds, Fund VIII was oversubscribed and reached its hard cap for limited partner commitments. This increases the firm's capital raised to $9.4 billion across 18 funds.

Committed capital includes the Qiming Venture Partners Fund VIII main fund that focuses on early and growth stage Technology and Consumer (T&C) and Healthcare investments and the Qiming Venture Partners Fund VIII-HC parallel healthcare fund that invests alongside the main fund (collectively "Fund VIII").

Fund VIII is led by Managing Partners Duane Kuang, Nisa LeungWilliam Hu, and Gary Rieschel, with full support of investment and administration teams based in ShanghaiBeijingShenzhen, and Hong Kong.

Since its inception in 2006, Qiming has demonstrated its ability to deliver consistently strong venture capital returns in China. Qiming has backed over 480 fast-growing companies, over 70 of which have achieved unicorn status. A vast majority of these companies were early stage at the time of initial investment. In addition, over 180 of our portfolio companies have achieved exits through IPO, M&A or other means, including Xiaomi, Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, APT Medical, Meituan, Bilibili and Roborock.

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close